Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | SOT102 |
Trade Name | |
Synonyms | SOT-102|SOT 102|SO N102|SO-N102|SON102 |
Drug Descriptions |
SOT102 is an antibody-drug conjugate (ADC) comprising a claudin 18.2 (CLDN18.2)-targeted antibody linked to a derivative of the cytotoxic anthracycline PNU-159682, which potentially leads to impaired DNA replication and protein synthesis, resulting in killing of tumor cells expressing CLDN18.2 (NCI Drug Dictionary). |
DrugClasses | CLDN18.2 Antibody 21 |
CAS Registry Number | NA |
NCIT ID | C190788 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin + SOT102 | Fluorouracil Leucovorin Nivolumab Oxaliplatin SOT102 | 0 | 1 |
Gemcitabine + Nab-paclitaxel + SOT102 | Gemcitabine Nab-paclitaxel SOT102 | 0 | 1 |
SOT102 | SOT102 | 0 | 1 |